Search company, investor...


Founded Year



Acquired | Acquired

Total Raised




About Metrika

Metrika, Inc. manufactures and sells single-use, hand-held, rapid-response medical diagnostic products to monitor diabetes. Metrika's first product, A1cNOW, aims to allow monitoring of HbA1c, the "gold standard" indicator of diabetes status and efficacy of disease management. The A1cNOW technology is a miniaturized photo-optical system that is single-use and aims to provide immediate results.

Headquarters Location

510 Oakmead Parkway P.O. Box 1676

Sunnyvale, California, 94085,

United States


Missing: Metrika's Product Demo & Case Studies

Promote your product offering to tech buyers.

Reach 1000s of buyers who use CB Insights to identify vendors, demo products, and make purchasing decisions.

Missing: Metrika's Product & Differentiators

Don’t let your products get skipped. Buyers use our vendor rankings to shortlist companies and drive requests for proposals (RFPs).

Expert Collections containing Metrika

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

Metrika is included in 2 Expert Collections, including Diabetes.



1,898 items


Health Monitoring & Diagnostics

702 items

Companies developing technology to facilitate near-patient and point-of-care (POC) in vitro diagnostic testing. Companies tagged as #NearPatient&POCTesting

Latest Metrika News

Italy’s private equity weekly roundup.

Nov 4, 2022

Metrika acquired the majority of CMC, an Italian producer and distributor of aerial platforms, from the Mastrogiacomo and Moretti families that retained Alantra as advisor (See here a previous post by BeBeez). CMC has sales in the region of 50 million euros. Charme Capital Partners won the auction for the acquisition of 70% of Tema Sinergie, an Italian developer of clynical solutions, on the ground […]

Metrika Frequently Asked Questions (FAQ)

  • When was Metrika founded?

    Metrika was founded in 1994.

  • Where is Metrika's headquarters?

    Metrika's headquarters is located at 510 Oakmead Parkway, Sunnyvale.

  • What is Metrika's latest funding round?

    Metrika's latest funding round is Acquired.

  • How much did Metrika raise?

    Metrika raised a total of $56.4M.

  • Who are the investors of Metrika?

    Investors of Metrika include Bayer, Oak Hill Capital Partners, Sutter Hill Ventures, Vertex Ventures Israel, Three Arch Partners and 4 more.

  • Who are Metrika's competitors?

    Competitors of Metrika include BioIQ, Intuity Medical, STARR Life Sciences, Cardiac Science Corporation, 20/20 GeneSystems and 12 more.

Compare Metrika to Competitors

STARR Life Sciences

STARR Life Sciences' aims to improve the efficacy of medical research by creating small-animal versions of human medical diagnostic and monitoring devices.

Intuity Medical Logo
Intuity Medical

Intuity Medical seeks to simplify diabetes management for persons living with diabetes. The company is developing a blood glucose monitoring system designed to make testing easy, convenient and discreet.

Nanogen Adavanced Diagnostics S.r.l.

At Nanogen, Inc., the company develop diagnostic products that enable physicians to deliver improved patient care. The company's products allow faster and easier diagnosis, treatment and monitoring of cardiovascular disease and infectious diseases. These products include molecular diagnostic kits and reagents, and rapid test kits, which can be used in urgent care settings or at the point-of-care. Nanogen has pioneered developments in areas involving biomarkers, molecular biology and nanotechnology. The company's business focus is to bring better results to diagnostics and healthcare.


Adlyfe was established to develop technologies for testing for early targets of amyloid diseases. Adlyfe is developing a test for the detection of amyloid proteins as early biomarkers of fatal brain diseases. The company's technology is based on the synthesis of small peptide ligands (Pronucleon ligands) which are amino acid sequence matched to target amyloids of interest. Ligand sequences are selected based on regions of the target protein known to undergo conformational changes associated with amyloid formation. Ligand sequence selection is the basis for diagnostic specificity. The interaction of the target amyloid protein with its ligands induces the ligands to undergo a conformational change that transduces a fluorescent signal or form an association with the target that can be detected. Further amplification of the signal is generated as additional ligands are nucleated to undergo conformational changes. This is the basis for sensitivity and ability to detect very low amyloid protein levels before symptoms occur.

Pelikan Technologies

Pelikan Technologies is dedicated to the development of hand-held diagnostic and monitoring devices capable of improving the screening and management of a variety of medical conditions. In addition to diabetes, the company's versatile technology platform has applications across a range of other medical conditions that involve blood screening and monitoring. Point-of-care testing and diagnostic panel test systems also represent markets that can benefit from Pelikan's technology. The Pelikan Sun can improve the quality of life for people with diabetes by combining several of the company's technologies into the most convenient and effective blood glucose self-monitoring device available. Pelikan's line of diabetes management tools will address the pain and inconvenience that has stymied the industry's manufacturers, and plagued people with diabetes, contributing to poor blood glucose monitoring compliance. By targeting these barr

hanse chemie GmbH

Micronics, Inc. is a developer of near patient in vitro diagnostic products for disease diagnosis, prognosis and treatment monitoring. The Company employs a core patent estate in microfluidics -- the ability to miniaturize complex tests onto credit card size disposable devices. Per the company, tests that today take hours to days in a central laboratory environment are processed on a Micronics disposable device in seconds to minutes.

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.